Study of a personalized vaccine for ovarian cancer after surgery
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a personalized vaccine made from your tumor's genetic material. It is given after surgery to help your immune system recognize and attack any remaining cancer cells, with the goal of preventing the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- You have epithelial ovarian cancer at stage II or III (FIGO 2014).
- You have had surgery (cytoreductive surgery) to remove visible tumors, with no obvious cancer left after surgery (R0/R1 resection).
- There is enough tumor tissue from your surgery to make the vaccine (either fresh tissue or special slides).
- The tumor has at least 5 'neoantigens' — unique markers your immune system can target (this is tested in the lab).
- You are generally in good health, with adequate organ function as shown by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your own tumor tissue called NeoOVSV. It is meant to train your immune system to fight any remaining cancer after surgery. The vaccine is a personal treatment because it uses your tumor's unique markers.
This trial tests a personalized cancer vaccine made from your own tumor cells. It is for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned after at least one round of platinum chemotherapy.
This Phase 1 study tests whether giving your own immune cells—engineered to target the FSH receptor—can control recurrent ovarian-related cancers. It’s mainly looking at safety and early signs of activity for patients whose cancer has not responded well to standard platinum chemotherapy.
This early-phase trial tests a lab-made immune cell treatment designed to recognize ovarian cancer and attack it. It may help people with high-risk ovarian cancer who still need effective options.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) that are trained to recognize specific markers on your ovarian cancer. The goal is to see if this vaccine is safe and helps your immune system fight the cancer.
This trial tests a personalized vaccine for people with epithelial ovarian cancer who still have a small amount of cancer DNA in their blood after surgery. The goal is to see if the vaccine can help stop the cancer from coming back.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.